| Online-Ressource |
Verfasst von: | Kayser, Sabine [VerfasserIn]  |
| Stadtherr, Peter [VerfasserIn]  |
| Uppenkamp, Michael [VerfasserIn]  |
| Bochtler, Tilmann [VerfasserIn]  |
| Hegenbart, Ute [VerfasserIn]  |
| Ho, Anthony Dick [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Krämer, Alwin [VerfasserIn]  |
Titel: | Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia |
Verf.angabe: | S. Kayser, A. Benner, C. Thiede, U. Martens, J. Huber, P. Stadtherr, J.W.G. Janssen, C. Röllig, M.J. Uppenkamp, T. Bochtler, U. Hegenbart, G. Ehninger, A.D. Ho, P. Dreger and A. Krämer |
E-Jahr: | 2016 |
Jahr: | 29 July 2016 |
Umfang: | 7 S. |
Fussnoten: | Gesehen am 11.02.2019 ; Im Titel ist "NPM1" kursiv geschrieben |
Titel Quelle: | Enthalten in: Blood cancer journal |
Ort Quelle: | London [u.a.] : Nature Publishing Group, 2011 |
Jahr Quelle: | 2016 |
Band/Heft Quelle: | 6(2016) Artikel-Nummer e449, 7 Seiten |
ISSN Quelle: | 2044-5385 |
Abstract: | The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight of the 67 patients had a FLT3-ITD (42%). Median age at transplantation was 54.7 years, median follow-up for survival from time of allografting was 4.9 years. At transplantation, 31 patients were in first, 20 in second complete remission (CR) and 16 had refractory disease (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR patients. Overall survival (OS) for patients transplanted in CR was significantly longer as compared to patients with RD (P=0.004), irrespective of whether the patients were transplanted in first or second CR (P=0.74). There was a highly significant difference in OS after allogeneic HSCT between pre-transplant MRD-positive and MRD-negative patients (estimated 5-year OS rates of 40 vs 89%; P=0.007). Multivariable analyses on time to relapse and OS revealed pre-transplant NPM1 MRD levels >1% as an independent prognostic factor for poor survival after allogeneic HSCT, whereas FLT3-ITD had no impact. Notably, outcome of patients with pre-transplant NPM1 MRD positivity >1% was as poor as that of patients transplanted with RD. |
DOI: | doi:10.1038/bcj.2016.46 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: http://dx.doi.org/10.1038/bcj.2016.46 |
| Volltext: https://www.nature.com/articles/bcj201646 |
| DOI: https://doi.org/10.1038/bcj.2016.46 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1587552213 |
Verknüpfungen: | → Zeitschrift |
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia / Kayser, Sabine [VerfasserIn]; 29 July 2016 (Online-Ressource)